CRECON MEDICAL ASSESSMENT

JP

Books

Books

  • Inoue S. Chapter 9. Cost-effectiveness analysis of drugs and  application to market access. Section 2. Cost-effectiveness analysis of drugs and utilization of drug price application. Technical Information Institute co,. LTD. 2019. (in Japanese)

  • Inoue S. Chapter 6. Health care, economic and value of self-injection, dropping to the doctors and the patient needs and product development for the valuation of self-injection. Self-injection to think from Section 2 medical economic point of view medical fee points. (Regulatory Science).2016. (in Japanese)

  • Kobayashi M. Model analysis in the medical economic evaluation. Basic medical economic evaluation -to understand cost-effectiveness definitely- (Regulatory Science).2015, Page.103-125.(in Japanese)

  • Kobayashi M. Specific method of utilizing Pharmacoeconomics. Technical Information Institute co,. LTD. (Nagase T et al eds). 2014. (in Japanese).2014.

  • Inoue S. Development strategy on the basis of the real condition and clinical condition, a mechanism of the treatment of sepsis. Technical Information Institute co,. LTD. (Hayakawa M et al eds). 2013. (in Japanese)

  • Inoue S. Chapter 9 The evaluation of a value and the price using the drug economics in the pre-filled syringe preparation. Material demand characteristics and inferior quality improvement of the pre-filled syringe preparation. Science & technology Co.,Ltd. (Shiraishi Y et al. eds). 2012. (in Japanese)

  • Kobayashi M. What is demanded now? A medical risk and quantitative approach. Medical risk management knowledge book. Japan Medical Publisher, Mano T. 2006, p. 23-45. (in Japanese)

  • Kobayashi M. Chapter5 Model analysis for clinical economics. Medical technology/Pharmaceutical products. (Keiso Shobo, Ikegami N, Nishimura S eds.) 2005; p.102-192. (in Japanese)

  • Kobayashi M. Chapter2 Why is trust not obtained? 1. Questionnaire results analysis about the choice of the medical institution. Hospital management of the trust recovery. (YAKUJI NIPPO LIMITED, Mano T ed) . 2005; p.25-35. (in Japanese)

  • Kobayashi M. Technology assessment and medical management-In case of pharmacoeconomics Medical management of the 21th century.( YAKUJI NIPPO LIMITED, Mano T ed) 2003; p.287-304. (in Japanese)

TOP
費用対効果分析

Cost-effectiveness analysis

To evaluate the cost-effectiveness of pharmaceuticals and medical devices by pharmacoeconomics (medical economic assessment), many specialized technologies and knowledge should be combined. We evaluate the cost-effectiveness of medical technologies using advanced modeling and statistical analysis technologies that we have developed over many years.

  • Cost-effectiveness analysis
  • Decision-making model construction
  • Review of previous studies
  • Systematic review
  • Indirect comparison/
    network meta-analysis
  • Budget impact analysis
    in the introduction of new pharmaceuticals
疾病負担分析

Burden of illness analysis

The socio-economic burden of disease is correlated with the therapeutic value of the disease. However, the estimation of such disease burdens is hardly done. We conduct burden of illness analysis to estimate epidemiological parameters, including the numbers of patients and events, long-term survival rates, and medical expenses.

  • Quantification of a target disease’s
    financial burden
  • Estimation and prediction of the number of patients
  • Estimation of lifetime medical expenses
  • Estimation of expected survival time
リアルワールドデータ

Real-world data/
Patient outcome data analyses

Real-world data, such as medical and receipt data, and patient outcome data are analyzed based on advanced statistical knowledge and technology.

  • Planning of survey/
    Development of protocols
  • Medical data analysis
  • Claims data analysis
  • QOL survey
  • Conjoint analysis/
    Discrete choice experiment (DCE)
  • Exploratory analysis
教育及び各種コンサルティング

Education
and other consulting services

We support in-house educational and enlightenment activities related to pharmacoeconomics (medical economic assessment) and health technology assessment (HTA), and provide consulting services. Furthermore, we provide consulting services based on review and summarization of technology appraisal (TA) by the UK’s National Institute for Health and Clinical Excellence (NICE).

  • Lecture/Workshop
  • Other consulting services
  • Review of NICE TA